Parabilis Medicines sets biotech record with $670m IPO
Parabilis Medicines has secured the largest initial public offering (IPO) in biotech history, suggesting that an uptick of upsized public…
Oncology
-
-
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at…
-
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting saw the presentation of several abstracts and presentations highlighting the…
-
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
Several abstracts and data presentations on emerging clinical research in non-small cell lung cancer prompted expert interest and discussion at…
-
ASCO26: In vivo oncology approaches continue to show promise
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting…
-
Emerging therapies for CNS tumours: key clinical trial updates to watch at ASCO 2026
At the 2026 American Society of Clinical Oncology (ASCO) annual congress, oral abstract presenters highlighted new and exciting central nervous…
-
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
At the 2026 American Society of Clinical Oncology (ASCO) annual congress, topline data from the Phase III RASolute 302 was…
-
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease
Platinum-sensitive ovarian cancer (PSOC) remains difficult to treat despite its responsiveness to mainstay platinum-based chemotherapies, as cumulative toxicities and diminishing…
-
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
During the American Society of Clinical Oncology (ASCO) meeting 2026, data were presented for a number of cancer vaccines, including…
-
ASCO26: BMS and J&J debut shining multiple myeloma data
Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting.…
